Aclarion announces key commercial milestone with completion of 1,000 nociscan exams

Pace of nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans further acceleration of scan volumes expected as mris are activated for the recently completed panel of 10 key opinion leader (kol) surgeons all commercial nociscans to date have been completed on siemens mri scanners with additional acceleration of volumes expected as philips scanners are onboarded broomfield, co, nov. 27, 2023 (globe newswire) -- via newmediawire -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed 1,000 commercial nociscan exams. “the milestone by itself is significant, but the pace of our commercial adoption is the most exciting aspect of achieving 1,000 commercial scans,” stated brent ness, ceo of aclarion.
ACON Ratings Summary
ACON Quant Ranking